Braso-Maristany, F;
Filosto, S;
Catchpole, S;
Marlow, R;
Quist, J;
Francesch-Domenech, E;
Plumb, DA;
... Tutt, AN; + view all
(2016)
PIM1 kinase regulates cell death, tumor growth and chemotherapy response in triple-negative breast cancer.
Nature Medicine
, 22
(11)
pp. 1303-1313.
10.1038/nm.4198.
Preview |
Text
emss-73638.pdf - Accepted Version Download (2MB) | Preview |
Abstract
Triple-negative breast cancers (TNBCs) have poor prognosis and lack targeted therapies. Here we identified increased copy number and expression of the PIM1 proto-oncogene in genomic data sets of patients with TNBC. TNBC cells, but not nonmalignant mammary epithelial cells, were dependent on PIM1 for proliferation and protection from apoptosis. PIM1 knockdown reduced expression of the anti-apoptotic factor BCL2, and dynamic BH3 profiling of apoptotic priming revealed that PIM1 prevents mitochondrial-mediated apoptosis in TNBC cell lines. In TNBC tumors and their cellular models, PIM1 expression was associated with several transcriptional signatures involving the transcription factor MYC, and PIM1 depletion in TNBC cell lines decreased, in a MYC-dependent manner, cell population growth and expression of the MYC target gene MCL1. Treatment with the pan–PIM kinase inhibitor AZD1208 impaired the growth of both cell line and patient-derived xenografts and sensitized them to standard-of-care chemotherapy. This work identifies PIM1 as a malignant-cell-selective target in TNBC and the potential use of PIM1 inhibitors for sensitizing TNBC to chemotherapy-induced apoptotic cell death.
| Type: | Article |
|---|---|
| Title: | PIM1 kinase regulates cell death, tumor growth and chemotherapy response in triple-negative breast cancer |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1038/nm.4198 |
| Publisher version: | https://doi.org/10.1038/nm.4198 |
| Language: | English |
| Additional information: | This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions. |
| Keywords: | Science & Technology, Life Sciences & Biomedicine, Biochemistry & Molecular Biology, Cell Biology, Medicine, Research & Experimental, Research & Experimental Medicine, MOLECULAR CHARACTERIZATION, PRECLINICAL MODELS, C-MYC, PHOSPHORYLATION, ACTIVATION, SUBTYPES, TRANSCRIPTION, PROGRESSION, INHIBITION, LEUKEMIA |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute > Research Department of Haematology UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute > Research Department of Oncology |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10055856 |
Archive Staff Only
 |
View Item |
